ACO represents an important subset of patients with asthma (15 to 35%) and COPD (10 to 40%) that might respond to drugs not typically indicated for the disorder corresponding to the patient's main diagnosis (eg, prescribing roflimulast / azithromycin in an patient diagnosed with asthma or T2 biologic therapies in a patient diagnosed with COPD.